Header Logo

Connection

Parameswaran Venugopal to Aged

This is a "connection" page, showing publications Parameswaran Venugopal has written about Aged.
Connection Strength

0.433
  1. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. Br J Haematol. 2017 Apr; 177(1):72-79.
    View in: PubMed
    Score: 0.055
  2. Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42.
    View in: PubMed
    Score: 0.049
  3. A patient with necrobiotic xanthogranuloma presenting with an anterior mediastinal mass, plasma cell dyscrasia, and a lymphoproliferative disorder. Clin Adv Hematol Oncol. 2011 Sep; 9(9):696-700.
    View in: PubMed
    Score: 0.038
  4. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011 Nov; 52(11):2097-104.
    View in: PubMed
    Score: 0.037
  5. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 2011 Apr 01; 117(7):1490-7.
    View in: PubMed
    Score: 0.036
  6. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023 06; 98(6):900-912.
    View in: PubMed
    Score: 0.021
  7. EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma. 2023 05; 64(5):1026-1034.
    View in: PubMed
    Score: 0.021
  8. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 12 01; 127(23):4421-4431.
    View in: PubMed
    Score: 0.019
  9. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica. 2021 07 01; 106(7):1932-1942.
    View in: PubMed
    Score: 0.019
  10. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021 01 21; 137(3):374-386.
    View in: PubMed
    Score: 0.018
  11. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest New Drugs. 2020 10; 38(5):1448-1453.
    View in: PubMed
    Score: 0.017
  12. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
    View in: PubMed
    Score: 0.016
  13. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 01; 35(31):3538-3546.
    View in: PubMed
    Score: 0.014
  14. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
    View in: PubMed
    Score: 0.012
  15. Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. J Leukoc Biol. 2013 Jan; 93(1):161-70.
    View in: PubMed
    Score: 0.010
  16. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104.
    View in: PubMed
    Score: 0.010
  17. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
    View in: PubMed
    Score: 0.009
  18. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 May; 7(6):406-12.
    View in: PubMed
    Score: 0.007
  19. Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab. Clin Adv Hematol Oncol. 2006 Jun; 4(6):439-41.
    View in: PubMed
    Score: 0.007
  20. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004 Aug; 28(8):791-803.
    View in: PubMed
    Score: 0.006
  21. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma. Clin Adv Hematol Oncol. 2004 Apr; 2(4):229-33.
    View in: PubMed
    Score: 0.006
  22. Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res. 2003 Aug; 12(4):443-50.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.